Karyopharm Therapeutics
KPTI
77 hedge funds and large institutions have $187M invested in Karyopharm Therapeutics in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 33 reducing their positions, and 16 closing their positions.
263% more call options, than puts
Call options by funds: $803K | Put options by funds: $221K
9% less funds holding
Funds holding: 85 → 77 (-8)
34% less capital invested
Capital invested by funds: $285M → $187M (-$97.6M)
48% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 33
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.06M |
| 2 |
JP Morgan Chase
New York
|
+$463K |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$315K |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$183K |
| 5 |
State Street
Boston,
Massachusetts
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$6.51M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$2.02M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$881K |
| 4 |
D.E. Shaw & Co
New York
|
-$632K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$630K |
KPTI Hedge Fund Activity: Q1 2016 in Review
77 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2016, worth a combined $187M — down 34% from $285M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of KPTI and 8 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 17 added.
The largest buyer was Wellington Management Group, adding an estimated $8.06M. The largest seller was Franklin Resources, cutting an estimated $6.51M.
- 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2016, down from 85 in Q4 2015.
- Funds reported $187M of Karyopharm Therapeutics stock for Q1 2016, down 34% quarter-over-quarter.
- 8 funds opened new Karyopharm Therapeutics positions in Q1 2016 and 16 closed out, a net change of -8 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2016 was Wellington Management Group, an estimated $8.06M added.
- The largest Karyopharm Therapeutics seller in Q1 2016 was Franklin Resources, an estimated $6.51M sold.
Based on aggregated 13F filings for Q1 2016.